PTC Therapeutics, Inc.

$PTCT gapped down and is the biggest loser on the Nasdaq right now after European regulators denied full approval for PTC’s drug Translarna for muscular dystrophy

Share This Article

 

About the Author

PTC Therapeutics, Inc.

Joey Ramson